Remove 2023 Remove Leads Remove Pharmacology
article thumbnail

New radiopharmaceutical laboratory opens in Germany

European Pharmaceutical Review

The facility will also have capacity to conduct non-clinical pharmacology studies for detailed characterisation of its first-in-class development candidates, according to Ariceum. Internet] European Pharmaceutical Review, Issue 3 2023. 1 References Jaafar-Thiel. Meeting rising demands of a new radiotheranostic era. cited 2024Mar].

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2023 is set to usher in a new era of genomics, and here are five areas where we should see significant advances. Just one mutation can lead to a complete change in protein formation. The post A new dawn of the genomic age: five areas set to be transformed in 2023 appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023.

FDA 85
article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience.

Medicine 102
article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

This could lead to significant research waste. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients. He leads the pre-clinical and clinical medical cannabis research programmes in Europe and is responsible for the cannabis clinic rollout across the continent.

Medical 98
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. million in sales by 2032. percent sales expected in 2032 within the seven major markets.

article thumbnail

Early diagnosis in Alzheimer’s disease: A first step towards better care

Clarivate

Timely and accurate diagnosis is critical to maximize the efficacy of available interventions – but for most individuals, the diagnostic journey remains long, complex and costly (Alzheimer’s Disease International, 2021; Chiari, 2022; Juganavar, 2023). Food and Drug Administration, 2023 and 2024). 2024; Quanterix, 2024).